{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-036563","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.893383+00:00","generated_at":"2026-06-08T22:28:57.577827+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ovid Therapeutics Q3 net loss $11.3M; secures $30M from Ligand for soticlestat royalty interest","bullets":["Received $30M from Ligand for 13% interest in soticlestat future royalties/milestones; cash runway extended into 2026.","Cash and equivalents $87.1M as of Sep 30, 2023, excluding the $30M received in Oct.","Net loss $11.3M ($0.16 per share) vs $12.0M ($0.17) in Q3 2022.","Takeda anticipates regulatory filings for soticlestat in fiscal year 2024; two Phase 3 trials on track.","OV329 expanding to IV formulation; IND expected H2 2024. OV350 (KCC2) IND also expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-036563","json":"https://secwatch.observer/filing/0001628280-23-036563.json","markdown":"https://secwatch.observer/filing/0001628280-23-036563.md","text":"https://secwatch.observer/filing/0001628280-23-036563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828023036563/0001628280-23-036563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828023036563/ovid-20231103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:28:57.577827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72b65702c9ef04f32ce341937d2fbb2973e020f7","claim":"Ovid Therapeutics Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 3, 2023, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Third Quarter 2023 Financial Results and Corporate Updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000162828023036563/0001628280-23-036563-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}